Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | CDC25B | P30305 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10392289 | 0.90 | KMT2A (0.58) | KMT2AALDH1A1KDM4EPOLBMAPT | |
| SCHEMBL11051219 | 0.79 | CA12 (0.59) | KMT2AALDH1A1KDM4EPOLBMAPT | |
| SCHEMBL351553 | 0.79 | CASP6 (0.57) | KMT2AALDH1A1POLBMAPTLMNA | |
| SCHEMBL15715983 | 0.79 | GABRA1 (0.49) | KMT2AALDH1A1KDM4EPOLBMAPT | |
| SCHEMBL10391503 | 0.78 | CDC25B (0.56) | KMT2AALDH1A1KDM4EPOLBMAPT | |
| SCHEMBL11052006 | 0.78 | ALDH1A1 (0.55) | KMT2AALDH1A1KDM4EPOLBMAPT | |
| SCHEMBL15788487 | 0.78 | CDC25B (0.52) | KMT2AALDH1A1KDM4EPOLBMAPT | |
| SCHEMBL23909538 | 0.77 | ALDH1A1 (0.54) | KMT2AALDH1A1MAPTGAAMEN1 | |
| SCHEMBL7061043 | 0.77 | ALDH1A1 (0.54) | KMT2AALDH1A1KDM4EPOLBMAPT | |
| SCHEMBL3559893 | 0.77 | TSHR (0.64) | KMT2AALDH1A1KDM4EPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106795146-B | Isoxazole derivatives as inhibitors of mutant isocitrate dehydrogenase 1 | 第一三共株式会社 | 2020-06-26 | — | — | CN | disclosed |
| US-10040791-B2 | Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-08-07 | — | — | US | disclosed |
| US-20170313696-A1 | ISOXAZOLE DERIVATIVE AS MUTANT ISOCITRATE DEHYDROGENASE 1 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-11-02 | — | — | US | disclosed |
| US-9546156-B2 | N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160280681-A1 | N-BICYCLIC ARYL,N'-PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-09-29 | — | — | US | disclosed |
| WO-2014078328-A1 | N-BICYCLIC ARYL,N'-PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| EP-1313696-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | ABBOTT LABORATORIES | 2002-03-21 | — | — | US | disclosed |
| WO-2002018323-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |
| CN-1046528-A | As the new naphthalane base-3H-1 of antihyperglycemic agents, 2,3,5-oxygen thia diazole 2-oxide compound | AMERICAN HOME PROD (US) | 1990-10-31 | — | — | CN | disclosed |
| US-4966975-A | Processes for the preparation of novel naphthalenylmethyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents | AMERICAN HOME PRODUCT | 1990-10-30 | — | — | US | disclosed |
| EP-0393941-A1 | Naphthalene derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-10-24 | — | — | EP | disclosed |
| US-4897405-A | Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-01-30 | — | — | US | disclosed |
| US-4490370-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1984-12-25 | — | — | US | disclosed |
| EP-0122155-A2 | Improvements in or relating to naphthylglycyl cephalosporin derivatives | ELI LILLY AND COMPANY (US) | 1984-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313696-A1 | ISOXAZOLE DERIVATIVE AS MUTANT ISOCITRATE DEHYDROGENASE 1 INHIBITOR | IDH1, IDH3A, IDH3B | KMT2A 202/4885ALDH1A1 307/4885KDM4E 188/4885 |
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | PPM1A, PTPRO, PTP4A1 | KMT2A 3246/4885ALDH1A1 299/4885KDM4E 2015/4885 |
| US-10040791-B2 | Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor | IDH1, IDH3A, IDH3B | KMT2A 202/4885ALDH1A1 307/4885KDM4E 188/4885 |
| US-20160280681-A1 | N-BICYCLIC ARYL,N'-PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | TK1, TNNI3K, CHUK | KMT2A 4134/4885ALDH1A1 2869/4885KDM4E 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.